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Summary
Molecular processes required for bone repair are a prerequisite for the development of new 
biological procedures for stimulation of bone healing. Currently, there is no adequate therapy 
available that can accelerate long bone fractures healing. Specifically there is a need for the de-
velopment of a new osteogenic device that will offer safe healing in particular of the trabecular 
bone. The Osteogrow project has developed a new therapy that promises to be safe and cost-
effective and might decrease the need for secondary interventions. The Osteogrow device conta-
ins an autologous blood coagulum (ABC) made from the peripheral blood and recombinant bone 
morphogenetic protein 6 (BMP6). BMP6 has been selected as compared to BMP2 or BMP7/OP1 
as it does not bind avidly to the BMP antagonist Noggin. ABC was chosen as a substrate for the 
delivery since BMP6 binds tightly to the number of plasma proteins resulting in the sustained and 
linear release over seven to ten days without provoking inflammation and immune responses. 
With support of the EU FP7 grant we have completed the preclinical development of Osteogrow 
and started Osteogrow first in humans (FIH) clinical studies. Osteogrow is tested clinically in two 
indications: the distal radial fracture and high tibial osteotomy to establish the safety and poten-
tial efficacy for Osteogrow for regeneration of the metaphyseal bone. Beyond currently tested 
clinical indications, this therapy would also be employed for posterolateral spinal fusion to treat 
degenerative spine disorders.   
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BONE REGENERATION 
Bone fracture healing is a tightly regulated process which entails a com-
plex series of biological events, with the interplay of different cell types and 
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the orchestration of several intracellular and extracellular signaling pathways. 
The first hours after trauma are characterized by hematoma formation and an 
acute inflammatory response. When injured, bones have a rare property of en-
dogenous self-repair by regenerating new bone without forming a fibrotic scar 
that would modify their mechanical characteristics. The healing of adult bones 
follows the steps mimicking of the bone formation during embryogenesis and 
organogenesis, where the regenerated bone is finally not distinguishable from 
the initial tissue (1). 
While the human population is aging, the incidence of bone trauma will 
increase. Although skeletal tissue has a robust regenerative capacity, the hea-
ling process may fail and result in delayed healing, malunions and non-unions. 
Susceptibility to bone fracture is also majored by an increasing number of wo-
men and men with osteoporosis. In the US and in the European Union (EU), 
about 5 and 10% of bone fractures exhibit disunion or late healing and therefore 
remain a key management in orthopedic surgery (2,3). Spinal fusions, fracture 
non-unions and repairs of critical-size bone defects caused by trauma, infecti-
ons, tumors, and abnormal skeletal development are some examples of surgeries 
frequently performed with important clinical need for the development of new 
healing possibilities to locally induce and stimulate the bone healing, but also to 
fill the bone defect and stimulate the physiological bone development, without 
donor site morbidity (4-7). 
A major limitation preventing the development of efficient therapies so far 
is the lack of an appropriate carrier for the delivery of osteoinductive molecu-
les (8-11) to cells during bone repair (12). The effectiveness of most morphogens 
critically depends on their concentration in the microenvironment, the kinetics 
of release and the stability of the protein. Release kinetics is defined by non-spe-
cific interactions between the protein and the material where boost release may 
lead to non-physiological, excessive micro environmental doses which result in 
edema, strong inflammatory reaction and ectopical ossification (13). In this pa-
per we will present a novel bone device OSTEOGROW containing all of the 
elements important for proper bone healing.
BMP THERAPY IN FRACTURE HEALING  
The bone morphogenetic proteins (BMPs) are growth and differentiation fac-
tors and form a large family of proteins structurally related to the TGF-β super 
family. BMPs signal through a set of specific Ser-Thr kinase receptors and act 
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under the influence of a concentration gradient, which is governed by extra-
cellular matrix proteins and BMP antagonists (14,15). BMPs serve as inductive 
signals for cell migration, growth, and subsequently differentiation. Osteogenic 
BMPs applied locally support formation of new bone, cartilage, and ligaments. 
Recombinant BMPs (BMP-2,-7 and-6) when implanted with an appropriate co-
llagenous matrix are capable of inducing new bone and this effect is dose de-
pendent (16-18). Currently, two rhBMP-based treatments have been approved for 
marketing in EU (BMP2 InductOS and BMP7 Osigraft /BMP7 Opgenra) and in 
both the BMP active ingredient is combined with a bovine-derived collagen ma-
trix (bovine collagen type 1). The FDA granted approval for the use of rhBMP2 
for the treatment of open tibial shaft fractures and fusion of the lumbar spine. 
BMP7 has been also approved as an alternative to autograft in compromised 
patients requiring revision posterolateral lumbar spinal fusion (3). Owing to its 
bovine source, the collagen must be highly purified to eliminate immunoge-
nicity and viral contamination and the risk cannot be completely eliminated. 
Therefore, the need still remains for a safe, effective and affordable means of 
delivering osteogenic proteins to the sites of bone defects. 
OSTEOGROW – NOVEL THERAPY FOR BONE REPAIR
A novel bone device is composed of rhBMP6 that was previously found in 
the plasma of healthy humans confirmed by proteomic analysis (19). rhBMP6 
has an important role in the body including involvement in a large number of 
physiological and pathophysiological processes. BMP6 is a paralog of BMP7 and 
rhBMP7 has been approved for treating tibial non-unions. BMP6 and BMP7 have 
high sequence similarity and act through the same receptor mechanisms and 
the profile of their biological effects is almost identical. The only major diffe-
rence is the higher potency of rhBMP6 regarding the bone formation because of 
its resistance to noggin, the BMP antagonist due to the amino acid lysin in the 
position 60 of the mature BMP6 domain. This lysine allows for reversible bin-
ding of BMP6 to Noggin, and unlike BMP7 or BMP2, BMP6 can dissociate from 
Noggin and escape from Noggin inhibition when binding to BMP receptors 
(20,21). This explains why BMP6 is more potent in promoting osteoblast diffe-
rentiation in vitro and inducing bone regeneration in vivo when compared with 
its closely related BMP7 paralog (20). The first hours after trauma are characteri-
zed by hematoma formation and inflammatory response where blood and bone 
marrow derived leukocytes initiate the healing process. During characterizati-
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on of rhBMP6 pharmacokinetic properties we discovered that it binds to blood 
components and disappears from the serum after blood coagulation (18,22-24). 
In experiments using rhBMP6 labeled with radioactive technetium (99mTc), it 
was proven that ABC serves as an ideal carrier for BMP6 since it tightly binds to 
the serum proteins. 
The new rhBMP6 containing medicinal product OSTEOGROW is composed 
of a biologically compatible autologous carrier ABC, to which small amounts of 
rhBMP6 are added to accelerate and enhance bone formation. Osteogenic acti-
vity may be detected using osteogenic assays that include ectopic bone forma-
tion in which a carrier and rhBMP6 are implanted at an ectopic site in a rodent 
and then monitored for bone formation (25). 
MECHANISM OF ACTION OF RHBMP6 IN OSTEOGROW 
Ectopic bone formation mediated by BMP6 and endogenous factors in the 
ABC containing extracellular matrix and soluble molecules serve as an incuba-
tor for the ectopic formation of new bone via ingrowth of surrounding blood 
vessels, and cells to initiate osteogenesis (Figure 1).
Figure 1. The rhBMP6 role in the new ectopic bone formation.
In in vivo testing of rhBMP6 activity in a rat subcutaneous assay  condensa-
tions of extracellular matrix (ECM) and cells are denser at day 3 of implantation 
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from which the cortical bone will form (Figure 2A). On day 7 bone is already for-
med in the area of peripheral condensations which is significantly earlier then 
with other carriers (Figure 2B). At day 35 there is a cortical bone formed outside 
the ossicle with trabecular bone and bone marrow inside the implant (Figure 2C). 
Implanted ABC with rhBMP6 did not exhibit inflammation and swelling which 
was observed with other commercial bone devices which use bovine collagen 
as carrier. 
Figure 2. Histology evaluation of ABC plus rhBMP6 in rat subcutaneous implants harvested at day 3, 
7 and 35 at an amount of 25 μg rhBMP6 per implant. A) Dashed black arrows denote condensation 
of cells of extracellular matrix; black arrows indicate the “yellow osteoprogenitor zone” within ABC 
gradually penetrated by cells from outside the ABC (asterix) (day 3); B) black arrowheads denote newly 
formed bone while oval arrow denotes hypertrophic chondrocytes in endochondral bone formation 
area (day 7); C) At day 35 there is a cortical bone formed outside the ossicle (black arrowheads) and 
trabecular bone with bone marrow inside the ossice. Size marker: left 200 μm (magnification 10×); 
middle image 200 μm (magnification 10×), right image 500 μm (magnification 4×).
Safety and efficacy studies have been conducted in the rat and rabbit and 
in the rabbit ulna critical size defect model (UCSD) (20,23,26-28). The UCSD 
implants consisted of ABC as a carrier to which different amounts of rhBMP6 
were added. A 1.5-centimeter segmental osteoperiostal defect was created in the 
middle of the ulna with an oscillating saw. The radius was left intact for mecha-
nical stability, and no internal or external fixation devices were used. The Oste-
ogrow implant was packed carefully into place to fill the defect. The soft tissues 
were closed meticulously in layers to contain the implant. Osteogrow preparati-
on included several steps: reconstitution of rhBMP6 with water for injection and 
mixing with freshly sampled blood and calcium chloride, incubation on room 
temperature for 60-90 minutes and maintaining red to deep red appearance in 
color and a cylindrical shape (Figure 3). 
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Figure 3. Osteogrow preparation. A) Blood withdrawal; B) Aspiration of the well-defined volume 
blood in a syringe; C) Mixing of freshly sampled blood with rhBMP6 and calcium chloride; D) 
Incubation of Osteogrow on room temperature for 60-90 minutes; E) Quality control of the 
Osteogrow implant before implantation.
The result showed that 100 µg of rhBMP6 in ABC enhanced the radiographic 
bone union across the defect and induced a complete radiographic osseous uni-
on. None of the control animals treated with ABC only (i.e., no BMP) achieved 
the full defect rebridgement (Figure 4).
Figure 4. Evaluation of Osteogrow efficacy on the new bone formation in the rabbit ulna segmental 
defect during the 19 week period. Rabbits (n=8 per group) treated with 100 μg rhBMP6 showed a 
complete restoration with cortical and trabecular bone in the diaphysis. 
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General toxicology studies were conducted in rats and rabbits while local tol-
erance of the implant was tested in rabbits. Single doses (30-450ug/kg) were safe, 
and similar amounts injected for 14 days did not cause any systemic toxicology 
signs. Also no signs of local intolerance after transcutaneous paraosseous injec-
tion or intraosseous implantation were observed (23). OSTEOGROW is currently 
clinically tested for bone repair. The initial Phase I/II study of fracture healing 
is conducted in patients with closed distal radius fracture (DRF) and high tibial 
osteotomy (HTO). It is the first trial of OSTEOGROW in humans. DRF is a two-
stage; no-treatment standard of care (SOC) controlled randomized trial, placebo 
(PBO) and one dose-level (SoC+ABC-rhBMP6 250mg, 1.0 mL). The total planned 
sample size is 75 and the trial consists of two stages: Stage 1A to address the 
“first-in-human” (FiH) safety evaluation and Stage 1B safety continuation test-
ing. The difference between stages is in the rate of patient enrollment. Stage 1 is 
planned to generate sufficient data (a total of 36 patients, enrollment 1:1:1) for a 
reasonable safety assessment to justify expansion of the trial to a 2nd site in Stage 
2. Progression between stages is determined by safety and tolerability. HTO is 
the first trial of Osteogrow with local intraosseal administration in varus defor-
mity of the forelegs. It is a randomized, double-blind, placebo controlled trial 
conducted in 2 stages to address Phase I-II clinical development. 
All enrolled patients (N=20) will receive the standard of care (SoC) and will 
be followed-up for 24 weeks with a post-trial follow-up for 18 months after the 
surgery (SoC time of removal of osteosynthetic material). They are being rando-
mized (2:1 in Stage 1 (N=6), 3:4 in Stage 2 (N=14), to obtain the final 1:1 assignment) 
in respect to locally administered treatment. Primary objectives are safety and 
tolerability and evaluation of systemic pharmacokinetics (PK) of rhBMP6 of a 
single dose of OSTEOGROW delivered locally and secondary objective is related 
to efficacy. Phase I DRF and Phase I HTO clinical study reports by Independent 
Drug Safety Monitoring Boards did not observe any serious side effect in pati-
ents following local implantation. A new indication for Osteogrow testing is the 
posterolateral interbody spinal fusion (PLIF), a technique used to treat a medical 
condition with inadequate pain management and poor efficacy in restoring load 
bearing capacity. Based on our preclinical data and preliminary evidence of sa-
fety in man, we believe that our novel bone device may represent a long term 
solution for the treatment of degenerative disc diseases. 
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Sažetak
OSTEOGROW – novi lijek za koštanu regeneraciju
Molekularni procesi potrebni za regeneraciju kosti su preduvjet za razvoj novih bioloških 
postupaka neophodnih za stimulaciju koštanog cijeljenja. U ovome trenutku na tržištu ne postoji 
adekvatna terapija koja može ubrzati cijeljenje prijeloma dugih kostiju. Postoji potreba za razvo-
jem nove koštane naprave koji će ponuditi sigurno i ekonomično liječenje. Projekt Osteogrow 
razvio je potpuno novu terapiju koja obećava da će biti sigurna i isplativa te će smanjiti potrebu 
za sekundarnim intervencijama. Osteogrow sadrži autologni krvni ugrušak (ABC) kao nosač koji 
se sastoji od periferne krvi u koji se dodaje rekombinantni protein BMP6 (engl. Bone Morphoge-
netic Protein). BMP6 je odabran kao poželjni koštani morfogentski protein u usporedbi s BMP2 
ili BMP7 / OP1 jer se ne veže na BMP antagonist, Noggin. Autologni krvni ugrušak odabran je 
kao nosač BMP6 molekule, jer se veliki broj proteina plazme čvrsto veže na BMP6. Uz potporu 
EU FP7 programa završena su pretklinička testiranja Osteogrow-a i započela je prva primjena 
Osteogrow lijeka u ljudi (FIH) unutar odobrene kliničke studije. Osteogrow se testira unutar dvije 
indikacije: distalna radijalna fraktura i visoka osteotomija goljenične kosti koje su odabrane  kako 
bi se utvrdila sigurnost i potencijalna učinkovitost Osteogrow lijeka u regeneraciji metafizalne 
kosti. Osim trenutno testiranih kliničkih indikacija, ova terapija će se koristiti za liječenje dege-
nerativnih bolesti kralježnice.
Ključne riječi: Osteogrow; BMP6; krvni nosač ; koštana regeneracija.
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